News

Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development
Chiesi and Arbor win EU orphan status for PH1 gene editing therapy
read more
Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics
Takeda’s oveporexton FDA decision tops GlobalData’s Q3 2026 biopharma catalysts
read more
Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
China IgA nephropathy approval highlights rising dual-target biologic competition
read more
Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
Racura treats first patient in Harness-1 lung cancer trial
read more
Biotech & Pharma Business,Clinical & Regulatory,Research & Development,Therapeutic Areas
EMBARC announces intention to collaborate with Insmed on landmark interventional study in bronchiectasis
read more
Digital & Data,Medical devices,Pharmaceuticals and therapeutics
Welbeck adopts OMED Health home-based SIBO testing pathway across UK network
read more
Biotech & Pharma Business,Drug Discovery & Development,Genomics and sequencing,Research & Development
Evogene advances ChemPass AI milestone in Google Cloud collaboration for autonomous small molecule discovery
read more
Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development
Al-S Pharma presents Phase 2 AP-101 data supporting misfolded SOD1 target in ALS at ENCALS 2026
read more
Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development
Thalia Therapeutics acquires Sanmirna and raises £2.75M to advance AML RNA therapy
read more
Drug Discovery & Development,Research & Development
FairJourney Bio expands antibody discovery offering through AbTherx partnership
read more
Biotech & Pharma Business,Digital & Data
Veeva acquires Copli and launches AI-powered content review platform
read more
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development
Absci reports positive Phase 1 data for hair loss antibody ABS-201
read more
Clinical & Regulatory,Digital & Data
Kayentis launches AI-powered eConsent tool for clinical trials
read more
Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas
Orphan Therapeutics Accelerator expands rare disease development network to advance ultra-rare therapies
read more
Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
Phase 2 trial begins for fetal growth restriction therapy with no approved drug treatments available
read more
Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
Oral GLP-1 candidate CX11 achieves 11.5% weight loss in US Phase 2 obesity trial
read more

Chiesi and Arbor win EU orphan status for PH1 gene editing therapy

Takeda’s oveporexton FDA decision tops GlobalData’s Q3 2026 biopharma catalysts

China IgA nephropathy approval highlights rising dual-target biologic competition

Racura treats first patient in Harness-1 lung cancer trial

EMBARC announces intention to collaborate with Insmed on landmark interventional study in bronchiectasis

Welbeck adopts OMED Health home-based SIBO testing pathway across UK network

Evogene advances ChemPass AI milestone in Google Cloud collaboration for autonomous small molecule discovery

Al-S Pharma presents Phase 2 AP-101 data supporting misfolded SOD1 target in ALS at ENCALS 2026

Thalia Therapeutics acquires Sanmirna and raises £2.75M to advance AML RNA therapy

FairJourney Bio expands antibody discovery offering through AbTherx partnership

Veeva acquires Copli and launches AI-powered content review platform

Absci reports positive Phase 1 data for hair loss antibody ABS-201

Kayentis launches AI-powered eConsent tool for clinical trials

Orphan Therapeutics Accelerator expands rare disease development network to advance ultra-rare therapies

Phase 2 trial begins for fetal growth restriction therapy with no approved drug treatments available

Oral GLP-1 candidate CX11 achieves 11.5% weight loss in US Phase 2 obesity trial

main menu

recent posts

Australian Phase 1 trial begins for CAR-T therapy targeting solid tumours

Atsena selects clinical candidate for Stargardt disease gene therapy

Quest Diagnostics expands access to molecular cancer testing through OncoEMR

get connected